Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.